

wise, it must be said that there are other complementary imaging techniques which should be evaluated to detect wall or luminal inflammation in extracranial arteries in the case of large vessel vasculitis such as GCA. It also has to be pointed out that ultrasound scan is of limited value in cases of aortitis.³

We understand that an algorithm should be used to decide whether a cohort has low or high clinical suspicion, deciding on the basis of the result whether or not to perform a superficial temporal artery biopsy. Nevertheless, this algorithm deserves its own particular debate (Fig. 1).

References

- González Porto SA, Silva Díaz MT, Reguera Arias A, Pombo Otero J, González Rodríguez A, Valero Gasalla J. Estudio comparativo de la ecografía Doppler frente a la biopsia de arteria temporal en el diagnóstico de la arteritis de células gigantes. *Reumatol Clin.* 2018; <http://dx.doi.org/10.1016/j.reuma.2018.08.007>. S1699-258X(18)30187.
 - de Miguel E, Monjo I. Respuesta a: Estudio comparativo de la ecografía Doppler frente a la biopsia de arteria temporal en el diagnóstico de la arteritis de células gigantes. *Reumatol Clin.* 2018; <http://dx.doi.org/10.1016/j.reuma.2018.11.001>.
 - Dejaco C, Ramiro S, Duftner C, Besson FJ, Bley TA, Blockmans D, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. *Ann Rheum Dis.* 2018; [77:636–43](http://dx.doi.org/10.1136/annrheumdis-2018-214000).
 - Schäfer VS, Juche A, Ramiro S, Krause A, Schmidt WA. Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. *Rheumatology (Oxford)*. 2017; [56:1479–83](http://dx.doi.org/10.1093/rheumatology/kex143). <http://dx.doi.org/10.1093/rheumatology/kex143>.
 - Aranda-Valera IC, García Carazo S, Monjo Henry I, de Miguel Mendieta E. Diagnostic validity of Doppler ultrasound in giant cell arteritis. *Clin Exp Rheumatol.* 2017; [103 Suppl 35:S123–7](http://dx.doi.org/10.1016/j.cler.2017.03.013).
 - Estrada Alarcón P, Reina D, Navarro Ángeles V, Cerdà D, Roig-Vilaseca D, Corominas H. Doppler ultrasonography of superficial temporal artery in a cohort of patients with strong clinical suspicion of giant cell arteritis. *Med Clin (Barc)*. 2018; [S0025-7753\(18\)30286-0](http://dx.doi.org/10.1016/j.medcli.2018.04.016). <http://dx.doi.org/10.1016/j.medcli.2018.04.016>.
- Héctor Corominas,^{a,*} Paula Estrada Alarcón,^b Patricia Moya,^a Dèlia Reina Sanz^b
- ^a Unitat territorial de Reumatologia i Malalties autoinmunes sistèmiques, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain
^b Servei de Reumatologia, Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain
- * Corresponding author.
E-mail address: vancor@yahoo.com
(H. Corominas).
- 2173-5743/ © 2019 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Application of the recommendations of the Spanish Society of Rheumatology on osteoporosis in a Fracture Liaison Service unit[☆]

Aplicación de las recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis en una unidad Fracture Liaison Service

Dear Editor:

The new recommendations for osteoporosis (OP) of the Spanish Society of Rheumatology (SER) propose criteria for initiation of OP treatment including patients with fragility fracture.¹ Thus, it is recommended that pharmacological treatment be started in patients >50 years with fragility fracture if they present: 1) Fractures of the hip or vertebra; 2) Other fragility fractures and low bone mineral density (BMD) defined by a T-score<−1 SD; 3) Patients with a high risk for hip fracture according to FRAX® with BMD ≥ 3%, and 4) Patients being treated with prednisone at a dose ≥5 mg/d. The SER recommendations were applied to a series of patients treated



Table 1

Total percentage of patients according to fracture type and treatment indication applying SER 2018 recommendations.

	Total number	DXA T-score<−1	Normal DXA, hip FRAX® ≥3%	Hip FRAX® ≥3% without DXA	Treatment indication SER 2018 recommendations
Hip	580 (26.8)	280/301 (93.0)	10/21 (47.6)	253/275 (92.0)	580 (100)
Vertebra	221 (10.2)	144/159 (90.5)	1/14 (7.1)	50/62 (80.6)	221 (100)
Forearm	662 (30.6)	505/585 (86.4)	6/80 (7.5)	43/85 (50.5)	554 (83.6)
Humerus	439 (20.3)	343/388 (88.4)	4/45 (8.8)	27/50 (54.0)	374 (85.1)
Other	260 (12.0)	182/235 (77.4)	2/52 (3.8)	7/26 (26.9)	191 (73.4)

BMD: Bone Mineral Density; FRAX®: Fracture Risk Assessment Tool; SER: Spanish Society of Rheumatology.
The values represent No. (%).

[☆] Please cite this article as: Rubiño F, Ojeda S, Molina A, Naranjo A. Aplicación de las recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis en una unidad Fracture Liaison Service. *Reumatol Clin.* 2021; [17:122–123](http://dx.doi.org/10.1016/j.reuma.2021.01.001).

In relation to sex, treatment for forearm fractures was indicated in 67% of the men and 85% of the women, for humerus fractures in 82% of the men and 86% of the women, and for other fractures in 62% of the men and 75% of the women.

Previous SER recommendations on OP indicated that all low-intensity trauma fractures should be treated, regardless of BMD value.² A study comparing different international guidelines concluded that in secondary prevention the percentage of candidates for treatment was 54%–100% in females and 26%–81% in males.³ In hip fractures, the figure was 81%–100% and in forearm fractures 36%–93%.

In conclusion, the new criteria for treatment of fragility fracture according to SER recommendations involve treating 89% of patients over 50 years of age, 100% of hip and vertebrae fractures, and 84% of other types of fracture. In patients in whom DXA is not available, the percentage with FRAX® treatment criteria is around 69% (100% of hip and vertebra, and 48% with other fractures).

References

- Naranjo Hernández A, Díaz del Campo Fontecha P, Aguado Acín M, Arboleya Rodríguez L, Casado Burgos E, Castañeda S, et al. Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis. *Reumatol Clín.* 2018; <http://dx.doi.org/10.1016/j.reuma.2018.09.004>.
 - Pérez Edo L, Alonso Ruiz A, Roig Vilaseca D, García Vadillo A, Guanabens Gay N, Peris P, et al. Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis. *Reumatol Clín.* 2011;7:357–79, <http://dx.doi.org/10.1016/j.reuma.2011.05.013>.
 - Naranjo A, Ojeda-Bruno S, Francisco-Hernández F, Erausquin C, Rúa-Figueroa I, Rodríguez-Lozano C. Aplicación de las guías de prevención secundaria de fractura osteoporótica y del índice FRAX en una cohorte de pacientes con fractura por fragilidad. *Med Clín.* 2011;136:290–2, <http://dx.doi.org/10.1016/j.medcli.2010.06.028>.
- Francisco Rubiño,* Soledad Ojeda, Amparo Molina, Antonio Naranjo
- Servicio de Reumatología, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas, Spain*
- * Corresponding author.
E-mail address: frubijuarez@gmail.com (F. Rubiño).
- 2173-5743/ © 2019 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.